Dr. Laura Sepp-Lorenzino is Executive Vice President, Chief Scientific Officer at Intellia Therapeutics, a company developing curative genome editing treatments to positively transform the lives of people with genetic diseases. She oversees all drug research across in vivo and engineered cell therapy areas at Intellia. Previously, she was VP, Head Nucleic Acid Therapies at Vertex Pharmaceuticals and before that, VP, Entrepreneur-in-Residence at Alnylam, a leader in the development of RNAi Therapeutics. At Alnylam, Laura was responsible for the Hepatic Infectious Disease Strategic Therapeutic Area, championed Extra Hepatic siRNA Delivery internally, and via a number of collaborations, was active in licensing and partnering. Before joining Alnylam, she spent 14 years at Merck & Co., having most recently served as Executive Director and Department Head, RNA Therapeutics Discovery Biology. In this role, Laura was responsible for identification and optimization of siRNAs and delivery vehicles, advancement of preclinical candidates, and development of an siRNA-conjugate platform to expand the repertoire of tissues accessible to in vivo siRNA delivery. Prior to her work with RNAi, Laura led the Cancer Research Department at Merck West Point, where she managed oncology drug discovery and development. She began her career in academia, as an Assistant Lab Member and Assistant Attending Molecular Biologist at Memorial Sloan-Kettering Cancer Center. Laura received her Professional Degree in Biochemistry from the University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York University.